Also, CRISPR-Cas9 mediated knockdown of AIM2 (absent in melanoma 2), an inflammation related gene in GBM cells, reduces cell growth and increases sensitivity to TMZ [83]. The gene discussed is AIM2; the disease is glioblastoma.